



EVALUATION OF INHALED COLISTIN TREATMENT IN PATIENTS WITHOUT CYSTIC FIBROSIS (CF) CP-143

Vallinas Hidalgo, S; Perez España, Z; Loizaga Diaz, I; Llona Armada, A; Pardo Santos, N ; Alvarez Lavin, MM; Leal Arranz, MV; Yurrebaso Ibarretxe, MJ.
Basurto University Hospital, Bilbao, Spain

Objective:

To evaluate the way inhaled colistin is used, its effectiveness and economic impact on patients who do not have CF.

Demographics: 13 females
Mean age: 74,8
Treatment mean duration: 16,56 month

Material and Methods:

- Retrospective evaluation
- 24 patients included (on colistin treatment for at least 6 months)
- Demographics
- Hospital admission for respiratory exacerbations
- Emergency episodes

Results:

<u>Hospital admission</u>		
<u>Before</u>	vs	<u>After</u>
1,52 (8,37d)		0,79 (5,45d)
-1402,9€/patient		
<u>Emergency Episodes</u>		
<u>Before</u>	vs	<u>After</u>
1,87		1,45

Efficacy

- Hospitalization related expenditure
- Colistine treatment cost

Costs analysis

Discussion:

Though there is not statistically significant difference, inhaled colistin may be a cost-effective option to treat patients with P. aeruginosa infected bronchiectasis